Neurosense Therapeutics (NRSN) said late Friday it received a letter from the Nasdaq Listing Qualifications Department on Thursday stating that it has not regained compliance with the Nasdaq listing rule requiring a minimum market value of listed securities of $35 million.
The company said it intends to appeal the staff determination by timely requesting a hearing before the Nasdaq Hearings Panel and seeking more time to regain compliance.
Neurosense said it has received written notification from the staff confirming that it has regained compliance with the Nasdaq listing rule requiring securities to maintain a minimum bid price of $1 per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.